|
1
|
Alqassab DF, Hasan MJ, AlSaadoon AM,
AlMuqahwi AJ, AlAwadhi FA, Bahram SA and Alsayyad AS: Prevalence
and risk factors of gastroesophageal reflux disease among adults
attending primary healthcare in Bahrain. J Family Med Prim Care.
13:5758–5765. 2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Iwakiri K, Fujiwara Y, Manabe N, Ihara E,
Kuribayashi S, Akiyama J, Kondo T, Yamashita H, Ishimura N,
Kitasako Y, et al: Evidence-based clinical practice guidelines for
gastroesophageal reflux disease 2021. J Gastroenterol. 57:267–285.
2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
El-Serag HB: Time trends of
gastroesophageal reflux disease: A systematic review. Clin
Gastroenterol Hepatol. 5:17–26. 2007.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Fujiwara Y and Arakawa T: Epidemiology and
clinical characteristics of GERD in the Japanese population. J
Gastroenterol. 44:518–534. 2009.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Wickramasinghe N and Devanarayana NM:
Insight into global burden of gastroesophageal reflux disease:
Understanding its reach and impact. World J Gastrointest Pharmacol
Ther. 16(97918)2025.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Vakil N, Sander ZV, Peter K, John D and
Roger J: The Montreal definition and classification of GERD. Am J
Gastroenterol. 101:1900–1920. 2006.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Katz PO, Gerson LB and Marcelo VF:
Guidelines for the diagnosis and management of GERD. Am J
Gastroenterol. 108:308–328. 2013.PubMed/NCBI
|
|
8
|
Shaheen NJ and Richter JE: Barrett's
esophagus. N Engl J Med. 360:925–935. 2009.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Manabe N, Yoshihara M, Sasaki A, Tanaka S,
Haruma K and Chayama K: Clinical characteristics and natural
history of patients with low grade reflux esophagitis. J
Gastroenterol Hepatol. 17:949–954. 2002.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Savarino E, Marabotto E, Bodini G,
Pellegatta G, Coppo C, Giambruno E, Brunacci M, Zentilin P and
Savarino V: Epidemiology and natural history of gastroesophageal
reflux disease. Minerva Gastroenterol Dietol. 63:175–183.
2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Andersson K and Carlsson E:
Potassium-competitive acid blockade: A new therapeutic strategy in
acid-related diseases. Pharmacol Ther. 108:294–307. 2005.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hori Y, Imanishi A, Matsukawa J, Tsukimi
Y, Nishida H, Arikawa Y, Hirase K, Kajino M and Inatomi N:
1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine
monofumarate (TAK-438), a novel and potent potassium-competitive
acid blocker for the treatment of acid-related diseases. J
Pharmacol Exp Ther. 335:231–238. 2010.
|
|
13
|
Ashida K, Sakurai Y, Nishimura A, Kudou K,
Hiramatsu N, Umegaki E, Iwakiri K and Chiba T: Randomised clinical
trial: A dose-ranging study of vonoprazan, a novel
potassium-competitive acid blocker, vs. lansoprazole for the
treatment of erosive oesophagitis. Aliment Pharmacol Ther.
42:685–695. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Jenkins H, Sakurai Y, Nishimura A, Okamoto
H, Hibberd M, Jenkins R, Yoneyama T, Ashida K, Ogama Y and
Warrington S: Randomised clinical trial: Safety, tolerability,
pharmacokinetics and pharmacodynamics of repeated doses of
TAK-438(vonoprazan), a novel potassium-competitive acid blocker, in
healthy male subjects. Aliment Pharmacol Ther. 41:636–648.
2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Sakurai Y, Mori Y, Okamoto H, Nishimura A,
Komura E, Araki T and Shiramoto M: Randomised clinical trial:
Acid-inhibitory effect of vonoprazan 20 mg compared with
esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male
subjects-a randomised open-label cross-over study. Aliment
Pharmacol Ther. 42:719–730. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Oshima T and Miwa H: Potent
Potassium-competitive Acid Blockers: A new era for the treatment of
Acid-related diseases. J Neurogastroenterol Motil. 24:334–344.
2018.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Kinoshita Y, Ishimura N and Ishihara S:
Management of GERD: Are Potassium-Competitive acid blockers
superior to proton pump inhibitors? Am J Gastroenterol.
113:1417–1419. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Oshima T, Arai E, Taki M, Kondo T, Tomita
T, Fukui H, Watari J and Miwa H: Randomised Clinical trial:
Vonoprazan versus lansoprazole for the initial relief of heartburn
in patients with erosive oesophagitis. Aliment Pharmacol Ther.
49:140–106. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ashida K, Sakurai Y, Hori T, Kudou K,
Nishimura A, Hiramatsu N, Umegaki E and Iwakiri K: Randomised
clinical trial: Vonoprazan, a novel potassium-competitive acid
blocker, vs. lansoprazole for the healing of erosive oesophagitis.
Aliment Pharmacol Ther. 43:240–251. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Akazawa Y, Fukuda D and Fukuda Y:
Vonoprazan-based therapy for Helicobacter pylori
eradication: Experience and clinical evidence. Therap Adv
Gastroenterol. 9:845–852. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Hoshino S, Kawami N, Takenouch N, Umezawa
M, Hanada Y, Hoshikawa Y, Kawagoe T, Sano H, Hoshihara Y, Nomura T
and Iwakiri K: Efficacy of Vonoprazan for proton pump
inhibitor-resistant reflux esophagitis. Digestion. 95:156–161.
2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Iwakiri K, Sakurai Y, Shiino M, Okamoto H,
Kudou K, Nishimura A, Hiramatsu N, Umegaki E and Ashida K: A
randomized, double-blind study to evaluate the acid-inhibitory
effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump
inhibitor-resistant erosive esophagitis. Ther Adv Gastroenterol.
10:439–451. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Okamura M, Nakahara K, Iwakura N, Hasegawa
T, Oyama M, Inoue A, Ishizu H, Satoh H and Fujiwara Y: Factors
associated with Patassium-competitive acid blocker Non-response in
patients with proton pump Inhibitor-refractory gastroesophageal
reflux disease. Digestion. 95:281–287. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Mizuno H, Nishino M, Yamada K,
Kamiyamamoto S and Hinoue Y: Efficacy of vonoprazan for 48-week
maintenance therapy of patients with healed reflux esophagitis.
Digestion. 101:411–421. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Tanabe T, Hoshino S, Kawami N, Hoshikawa
Y, Hanada Y, Takenouchi N, Goto O, Kaise M and Iwakir K: Efficacy
of long-term maintenance therapy with 10-mg vonoprazan for proton
pump inhibitor-resistant reflux esophagitis. Esophagus. 16:377–381.
2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Shinozaki S, Sakamoto H, Osawa H, Yano T,
Lazaridis N and Yamamoto H: Timing and predictors for Vonoprazan
dose escalation in refractory gastroesophageal reflux disease: A
Long-term observational study. Digestion: 1-9 doi:
10.1159/000546992 (Epub ahead of print).
|
|
27
|
Armstrong D, Bennett JR, Blum AL, Dent J,
Dombal FTD, Galmiche JP, Lundell LR, Margulies M, Richter JE,
Spechler SJ, et al: The endoscopic assessment of esophagitis: A
progress report on observer agreement. Gastroenterology. 111:85–92.
1996.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Kusano M, Shimoyama Y, Sugimoto S,
Kawamura O, Maeda M, Minashi K, Kuribayashi S, Higuchi T, Zai H,
Ino K, et al: Development and evaluation of FSSG: Frequency scale
for the symptoms of GERD. J Gastroenterol. 39:888–891.
2004.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Shinozaki S, Osawa H, Miura Y, Hayashi Y,
Sakamoto H, Yano T, Lefor AK and Yamamoto H: Long-term changes in
serum gastrin levels during standard dose vonoprazan therapy. Scand
J Gastroenterol. 57:1412–1416. 2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Hoshihara Y: Endoscopic findings of GERD.
Nihon Rinsho. 62:1459–1464. 2004.PubMed/NCBI(In Japanese).
|
|
31
|
Miwa H, Yokoyama T, Hori K, Sakagami T,
Oshima T, Tomita T, Fujiwara Y, Saita H, Itou T, Ogawa H, et al:
Interobserver agreement in endoscopic evaluation of reflux
esophagitis using a modified Los Angeles classification
incorporating grades N and M: A validation study in a cohort of
Japanese endoscopists. Dis Esophagus. 21:355–363. 2008.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Kinoshita Y and Adachi K: Hiatal hernia
and gastroesophageal flap valve as diagnostic indicators in
patients with gastroesophageal reflux disease. J Gastroenterol.
41:720–721. 2006.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kimura K and Takemoto T: An endoscopic
recognition of the atrophic border and its significance in chronic
gastritis. Endoscopy. 1:87–97. 1969.
|
|
34
|
Uemura N, Kinoshita Y, Haruma K, Kushima
R, Yao T, Akiyama J, Aoyama N, Baba Y, Suzuki C and Ishiguro K:
Vonoprazan as a Long-term maintenance treatment for erosive
esophagitis: VISION, a 5-Year, randomized, Open-label study. Clin
Gastroenterol Hepatol. 23:748–757.e5. 2025.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Gyawali CP, Kahrilas PJ, Savarino E,
Zerbib F, Mion F, Smout AJPM, Vaezi M, Sifrim D, Fox MR, Vela MF,
et al: Modern diagnosis of GERD: The Lyon Consensus. Gut.
67:1351–1362. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Dent J, Brun J, Fendrick A, Fendrick M,
Janssens J, Kahrilas P, Lauritsen K, Reynolds J, Shaw M and Tally
N: An evidence-based appraisal of reflux disease management-the
Genval Workshop Report. Gut. 44 (Suppl 2):S1–S16. 1999.PubMed/NCBI View Article : Google Scholar
|
|
37
|
DeVault KR and Castell DO: American
College of Gastroenterology. Updated guidelines for the diagnosis
and treatment of gastroesophageal reflux disease. Am J
Gastroenterol. 100:190–200. 2005.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Kim SY and Lee KJ: Potential risks
associated with Long-term use of proton pump inhibitors and the
maintenance treatment modality for patients with mild
gastroesophageal reflux disease. J Neurogastroenterol Motil.
30:407–20. 2024.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Huh CW, Son NH, Youn YH, Jung DH, Kim MK,
Gong EJ, Huh KC, Kim SY, Park MI, Lee JY, et al: Real-world
prescription patterns and patient satisfaction regarding
maintenance therapy of gastroesophageal reflux disease: An
observational, Cross-sectional, multicenter study. J
Neurogastroenterol Motil. 29:470–477. 2023.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Laine L, DeVault K, Katz P, Mitev S, Lowe
J, Hunt B and Spechler S: Vonoprazan versus lansoprazole for
healing and maintenance of healing of erosive esophagitis: A
randomized trial. Gastroenterology. 164:61–71. 2023.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Ashida K, Iwakiri K, Hiramatsu N, Sakurai
Y, Hori T, Kudou K, Nishimura A and Umegaki E: Maintenance for
healed erosive esophagitis: Phase III comparison of vonoprazan with
lansoprazole. World J Gastroenterol. 24:1550–1561. 2018.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Xiao Y, Qian J, Zhang S, Dai N, Chun HJ,
Chiu C, Chong CF, Funao N, Sakurai Y, Eisner JD, et al: Vonoprazan
10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in
Asian patients with healed erosive esophagitis: A randomized
controlled trial. Chin Med J (Engl). 137:962–971. 2024.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Malfertheiner P, Nocon M, Vieth M, Stolte
M, Jaspersen D, Koelz HR, Labenz J, Leodolter A, Lind T, Richter K
and Willich SN: Evolution of gastro-oesophageal reflux disease over
5 years under routine medical care-the ProGERD study. Aliment
Pharmacol Ther. 35:154–164. 2012.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Ness-Jensen E, Lindam A, Lagergren J and
Hveem K: Changes in prevalence, incidence and spontaneous loss of
gastro-oesophageal reflux symptoms: A prospective Population-based
cohort study, the HUNT study. Gut. 61:1390–1397. 2012.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Shah A, Shibli F, Kitayama Y and Fass R:
The natural course of gastroesophageal reflux disease: A critical
appraisal of the literature. J Clin Gastroenterol. 55:12–20.
2021.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Shaqran TM, Ismaeel MM, Alnuaman AA, Al
Ahmad FA, Albalawi GA, Almubarak JN, AlHarbi RS, Alaqidi RS, ALALi
YA, Alfawaz KS, et al: Epidemiology, causes, and management of
Gastro-esophageal reflux disease: A systematic review. Cureus.
15(e47420)2023.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Nocon M, Labenz J, Jaspersen D,
Meyer-Sabellek W, Stolte M, Lind T, Malfertheiner P and Willich SN:
Long-term treatment of patients with gastro-oesophageal reflux
disease in routine care-results from the ProGERD study. Aliment
Pharmacol Ther. 25:715–722. 2007.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Armstrong D: Systematic review:
Persistence and severity in gastro-oesophageal reflux disease.
Aliment Pharmacol Ther. 28:841–853. 2008.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Hsu PI, Lu CL, Wu DC, Kuo CH, Kao SS,
Chang CC, Tai WC, Lai KH, Chen WC, Wang HM, et al: Eight weeks of
esomeprazole therapy reduces symptom relapse, compared with 4
weeks, in patients with Los Angeles grade A or B erosive
esophagitis. Clin Gastroenterol Hepatol. 13:859–866.e1.
2015.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Jung DH, Youn YH, Jung HK, Kim SY, Huh CW,
Shin CM, Oh JH, Huh KC, Park MI, Choi SC, et al: On-demand versus
continuous maintenance treatment with a proton pump inhibitor for
mild Gastroesophageal reflux disease: A prospective randomized
multicenter study. J Neurogastroenterol Motil. 29:460–469.
2023.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Umezawa M, Kawami N, Hoshino S, Hoshikawa
Y, Koizumi E, Takenouchi N, Hanada Y, Kaise M and Iwakiri K:
Efficacy of on-demand therapy using 20-mg vonoprazan for mild
reflux esophagitis. Digestion. 97:309–315. 2018.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Okanobu H, Kohno T, Boda K, Ochi H and
Furukawa Y: Long-term clinical course after successful initial
treatment in patients with mild erosive esophagitis: A prospective
Follow-Up study. Digestion. 104:283–290. 2018.PubMed/NCBI View Article : Google Scholar
|
|
53
|
McCarthy DM: Proton pump inhibitor use,
Hypergastrinemia, and gastric carcinoids-what is the relationship?
Int J Mol Sci. 21(662)2020.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Fossmark R, Johnsen G, Johanessen E and
Helge W: Rebound acid hypersecretion after long-term inhibition of
gastric acid secretion. Aliment Pharmacol Ther. 21:149–154.
2005.PubMed/NCBI View Article : Google Scholar
|
